Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I single-agent, dose-escalating, multiple-dose trial of SF 1126 in patients with multiple myeloma and B-cell malignancies, including chronic lymphocytic leukaemia, indolent non-Hodgkin's lymphoma, and mantle cell lymphoma (MCL)

Next Previous
Trial Profile

Phase I single-agent, dose-escalating, multiple-dose trial of SF 1126 in patients with multiple myeloma and B-cell malignancies, including chronic lymphocytic leukaemia, indolent non-Hodgkin's lymphoma, and mantle cell lymphoma (MCL)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SF 1126 (Primary)
  • Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Semafore Pharmaceuticals

    • Most Recent Events

    • 10 Nov 2010 Results from patients with B-cell malignancies will be presented at ASH-2010, according to a Semafore Pharmaceuticals media release.
    • 22 Jun 2010 Preliminary results indicating activity in patients with CLL presented at the Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference, according to a Semafore Pharmaceuticals media release.
    • 21 Apr 2010 The first patient with a B-cell malignancy was dosed in April 2010, as reported by a Semafore Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top